Figure 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial

Read full text Summarise with VIRAT
Authors: Joanne Barnes Weidhaas, Jonathan Harris, Maura L. Gillison, Dukagjin M. Blakaj, Greg A. Krempl, Kristin Higgins, Jack Phan, Neal Dunlap, Shazia T. Mahamood, Jennifer Anne Dorth, Jimmy J. Caudell, Anand B. Desai
+8 more Thomas James Galloway, J. Daniel Pennington, Adam Currey, Jennifer A. Lathrop, Pedro A. Torres-Saavedra, D. Neil Hayes, Sue Sun Yom, Quynh‐Thu Le
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Grade 3 to 4 treatment-related AEs over time by KRAS and assigned treatment. Rates of treatment-related AEs with 95% CI by treatment and KRAS-variant status, with KRAS-variant patients being depicted by blue (cisplatin-treated) and red (cetuximab-treated) and nonvariant patients depicted by green (cisplatin-treated) and brown (cetuximab-treated).

Fields of Study & Subjects

Head and Neck Cancer Studies Esophageal Cancer Research and Treatment Oral health in cancer treatment

Publication details

Publication date
31 March 2026
Language
EN